Opendata, web and dolomites

BMPARK SIGNED

Development of BMP2 Neurotrophic Therapy for Parkinson’s Disease

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 BMPARK project word cloud

Explore the words cloud of the BMPARK project. It provides you a very rough idea of what is the project "BMPARK" about.

bmp2    me    brain    date    pd    century    nigra    neuroprotective    therapy    stakeholders    protect    function    communication    neurons    lewy    degeneration    levels    efficacy    individuals    vectors    economy    annum    consist    demographic    viral    total    accumulation    scientific    2030    aging    neurite    paralleled    socioeconomic    contribution    13    people    transformative    independence    modifying    mechanism    bmp    transgene    half    neurotrophic    substantia    extensive    neurodegenerative    societal    region    inclusions    worldwide    synuclein    multidisciplinary    axons    bone    billion    plans    progressive    maturity    despite    protein    career    intraneuronal    highlight    relevance    dopaminergic    investigation    morphogenetic    trials    training    direct    hallmarks    double    neuropathological    predominantly    therapies    intensive    motor    projected    signalling    million    molecular    midbrain    alpha    clinical    bodies    professional    parkinson    rat    disease    context    dopamine    model   

Project "BMPARK" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK 

Organization address
address: WESTERN ROAD
city: Cork
postcode: T12 YN60
website: www.ucc.ie

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Total cost 184˙590 €
 EC max contribution 184˙590 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2019
 Funding Scheme MSCA-IF-EF-ST
 Starting year 2020
 Duration (year-month-day) from 2020-09-01   to  2022-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY COLLEGE CORK - NATIONAL UNIVERSITY OF IRELAND, CORK IE (Cork) coordinator 184˙590.00

Map

 Project objective

Parkinson’s Disease (PD) is a progressive neurodegenerative disease. PD affects more than 6 million people worldwide while 1.2 million people have PD in Europe. For the European economy PD has a total socioeconomic cost of €13.9 billion per annum. With the aging demographic the number of individuals affects by PD are projected to double by 2030 highlight the need for disease modifying therapies. The neuropathological hallmarks of PD are the progressive loss of dopaminergic neurons in a region of the brain known as the substantia nigra in the midbrain, and the accumulation of intraneuronal inclusions called Lewy bodies and lewy neurite that consist predominantly of a protein called α-synuclein. Despite over half a century of investigation, there is no disease modifying therapy for PD. I propose that a protein called bone morphogenetic protein (BMP)2 can protect midbrain dopaminergic neurons in the PD brain. BMP2 is distinct from other neurotrophic factors used in the clinical trials to date in that it has a different signalling mechanism that can be targeted to protect dopaminergic neurons. Here I will assess the neuroprotective efficacy of viral vectors carrying the BMP2 transgene in the rat α-synuclein model of PD. I will determine if this molecular therapy can protect dopamine neurons and their axons against α-synuclein induced degeneration to maintain brain dopamine levels and improve motor function. To do this, I will use a multidisciplinary approach which will be paralleled by intensive training and career development opportunities to enable me to make a transformative contribution to knowledge and to achieve professional maturity and independence. In this way, this work has direct relevance for the future development of neurotrophic factors for clinical use in PD and the extensive dissemination and communication plans to target all stakeholders will ensure both societal and scientific impact in an European context and also for individuals with PD.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "BMPARK" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "BMPARK" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

NaWaTL (2020)

Narrative, Writing, and the Teotihuacan Language: Exploring Language History Through Phylogenetics, Epigraphy and Iconography

Read More  

WATCH (2019)

Wessex–Armorica: Territories, Connections and Hierarchies

Read More  

TOPOCIRCUS (2019)

Simulations of Topological Phases in Superconducting Circuits

Read More  
lastchecktime (2022-12-01 13:12:34) correctly updated